The deal includes a $200m cash payment from AbbVie at closing, subject to standard adjustments, alongside potential interim funding payments. Credit: © AbbVie Inc. All rights reserved.

AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim funding payments.

The acquisition includes Nimble’s investigational lead candidate, an oral peptide IL23R inhibitor currently in preclinical development for psoriasis, and a pipeline of new oral peptide candidates aimed at autoimmune diseases.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It also encompasses Nimble’s advanced peptide synthesis, screening and optimisation platform, which leverages proprietary technology to expedite the discovery and refinement of peptide candidates for diverse targets.

Nimble’s shareholders may obtain additional payments contingent on achieving a development milestone.

The transaction is pending customary closing conditions, including compliance with the Hart-Scott-Rodino Antitrust Improvements Act’s waiting period.

Nimble is supported by founding investors Roche Ventures and Telegraph Hill Partners.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AbbVie discovery research global head and senior vice-president Jonathon Sedgwick stated: “The addition of Nimble’s pipeline to AbbVie’s existing pipeline, combined with our deep clinical and translational expertise in immunology, represents an important growth opportunity.

“Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases.”

IL23R inhibitor is being explored as an oral therapy for psoriasis and inflammatory bowel disease (IBD).

IL23R is a validated therapeutic target in select autoimmune conditions, playing a significant role in the pathogenesis and progression of psoriasis and IBD by promoting inflammation and immune response amplification.

Nimble Therapeutics founder and CEO Jigar Patel stated: “Nimble Therapeutics is committed to transforming the discovery of oral peptide-based medicines. With AbbVie’s world-class expertise in developing and commercialising medicines on a global scale, Nimble’s novel oral therapies will be well-positioned to reach more people living with autoimmune diseases.”

In October 2024, AbbVie announced a partnership and option-to-license agreement with EvolveImmune Therapeutics, focusing on the development of next-generation cancer biotherapeutics.